Hoʻokuʻu ʻia ka lāʻau hoʻohui paʻa paʻa mua no ka maʻi maʻi type 2

Ua hoʻokumu ʻo Glenmark Pharmaceuticals Limited i kahi hui pū paʻa paʻa (FDC) o kahi mea hoʻohana nui DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, me Pioglitazone. ʻO kēia wale nō ka DPP4 a me Glitazone hui pū ʻana ma India no nā pākeke me ka maʻi maʻi type 2 ʻole. Ua hoʻokumu ʻo Glenmark i kēia FDC ma lalo o ka inoa inoa ʻo Zita Plus Pio, nona ka Teneligliptin (20 mg) + Pioglitazone (15 mg), e lawe ʻia i hoʻokahi lā.

Ma ka ʻōlelo ʻana e pili ana i ka hoʻomohala ʻana, ʻōlelo ʻo Alok Malik, Group Vice President & Head, India Formulations - Glenmark Pharmaceuticals, "ʻO ka maʻi diabetes kahi wahi koʻikoʻi no Glenmark; he paionia i ka hāʻawi ʻana i nā koho lapaʻau hou loa i nā maʻi maʻi diabetes ma India. Ua hauʻoli mākou i ka hoʻolauna ʻana i kēia moʻolelo Zita Plus Pio, ʻo ia ka mea mua o kāna ʻano ma India; ke hāʻawi nei i kahi koho lapaʻau papa honua a kūpono hoʻi i nā poʻe maʻi maʻi maʻi makua."

ʻO Glenmark ka hui mua ma India e kūʻai aku i ka FDC hou o Teneligliptin + Pioglitazone, i ʻae ʻia e ka DCGI (Drug Controller General of India). He mea pono kēia hui pū ʻana no ka poʻe maʻi e koi ana i ka mālama ʻana me Teneliglilitptin a me Pioglitazone (e like me nā lāʻau ʻokoʻa) e hoʻomaikaʻi i ka mana glycemic e hōʻemi ana i ka Insulin Resistance. 

ʻO ka maʻi maʻi type 2 ke kū pinepine nei i nā pilikia o ka maʻi β cell a me ka pale ʻana i ka insulin. Loaʻa iā Glenmark's FDC o Teneligliptin + Pioglitazone ka pono e hoʻoponopono i kēia mau pathophysiologies koʻikoʻi ʻelua e ʻoi aku ka maikaʻi o ka FDC i ka mālama ʻana i ka maʻi diabetes type 2. ʻO ka hui pū ʻana o Teneligliptin + Pioglitazone e hāʻawi i kahi ala synergistic kahi e hoʻomaikaʻi maikaʻi ai ʻo Teneligliptin i ka naʻau β cell, a ʻo Pioglitazone e hōʻemi pono i ka pale ʻana i ka insulin.

Hāʻawi ʻo Glenmark i ka mālama ʻana i ka maʻi diabetes

I ka makahiki 2015, ua hoʻololi ʻo Glenmark i ka mākeke maʻi maʻi ma o ka hoʻokuʻu ʻana i kāna DPP4 inhibitor - Teneligliptin ma India, a ukali ʻia e kahi FDC o Teneligliptin + Metformin. He hoʻoilina ikaika ʻo Glenmark ma mua o ʻehā mau makahiki o ka holomua a me ka hana hou. I ka hoʻomau ʻana i kāna manawa mua ma India hoʻoilina, ua hoʻokuʻu ʻo ia i ka FDC o Teneligliptin + Remogliflozin i 2021.

Ua ʻike ʻia ʻo India ʻo ke kapikala diabetes o ka honua. Wahi a ka International Diabetes Federation (IDF), ʻo ka prevalence o ka maʻi maʻi ma India ma kahi o 74 miliona mau mākua, i manaʻo ʻia e piʻi i 125 miliona (kokoke i ka 70% piʻi) e 2045[i]. Ma waho o kēia mau mea, 77% o nā maʻi i loaʻa i ka maʻi diabetes ʻole.